Oxbow Advisors LLC Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Oxbow Advisors LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,653 shares of the biopharmaceutical company's stock, valued at approximately $2,317,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Arizona State Retirement System grew its stake in Regeneron Pharmaceuticals by 1.5% in the 1st quarter. Arizona State Retirement System now owns 31,684 shares of the biopharmaceutical company's stock valued at $20,095,000 after purchasing an additional 460 shares during the period. Ballentine Partners LLC grew its stake in Regeneron Pharmaceuticals by 10.1% in the 1st quarter. Ballentine Partners LLC now owns 1,010 shares of the biopharmaceutical company's stock valued at $641,000 after purchasing an additional 93 shares during the period. B & T Capital Management DBA Alpha Capital Management grew its stake in Regeneron Pharmaceuticals by 11.5% in the 1st quarter. B & T Capital Management DBA Alpha Capital Management now owns 3,510 shares of the biopharmaceutical company's stock valued at $2,226,000 after purchasing an additional 363 shares during the period. Callahan Advisors LLC grew its stake in Regeneron Pharmaceuticals by 8.0% in the 1st quarter. Callahan Advisors LLC now owns 935 shares of the biopharmaceutical company's stock valued at $593,000 after purchasing an additional 69 shares during the period. Finally, Park Square Financial Group LLC grew its stake in Regeneron Pharmaceuticals by 266.7% in the 1st quarter. Park Square Financial Group LLC now owns 286 shares of the biopharmaceutical company's stock valued at $181,000 after purchasing an additional 208 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on REGN. Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective for the company. The Goldman Sachs Group cut their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Finally, BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research note on Monday, June 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $823.54.

Regeneron Pharmaceuticals Price Performance

REGN opened at $567.74 on Friday. The stock's 50 day simple moving average is $545.22 and its 200 day simple moving average is $619.85. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The firm has a market cap of $61.29 billion, a price-to-earnings ratio of 14.45, a PEG ratio of 2.11 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $9.55 earnings per share. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.62%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.